Orwoll, E.; Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, United States
Teglbjærg, C. S.; Center for Clinical and Basic Research, Ballerup 2750, Denmark
Langdahl, B. L.; Aarhus University Hospital, Aarhus 8000, Denmark
Chapurlat, R.; Institut National de la Santeet de la Recherche Medicale Unite Mixte de Recherche 1033, Université de Lyon, Hôpital Edouard Herriot, Lyon 69003, France
Czerwinski, E.; Krakow Medical Center, Krakow 31-501, Poland
Kendler, D. L.; University of British Columbia, Vancouver, BC V6H 3X8, Canada
REGINSTER, Jean-Yves ; Centre Hospitalier Universitaire de Liège - CHU > Médecine de l'appareil locomoteur
Kivitz, A.; Altoona Center for Clinical Research, Duncansville, PA 16635, United States
Lewiecki, E. M.; New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM 87106, United States
Miller, P. D.; Colorado Center for Bone Research, Lakewood, CO 80227, United States
Bolognese, M. A.; Bethesda Health Research Center, Bethesda, MD 20817, United States
McClung, M. R.; Oregon Osteoporosis Center, Portland, OR 97213, United States
Bone, H. G.; Michigan Bone and Mineral Clinic, Detroit, MI 48236, United States
Ljunggren, Ö.; Uppsala University, Uppsala 75185, Sweden
Abrahamsen, B.; University of Southern Denmark, Gentofte Hospital, Odense 5000, Denmark, University of Southern Denmark, Gentofte Hospital, Hellerup 2900, Denmark
Gruntmanis, U.; Dallas Veterans Affairs Medical Center, University of Texas Southwestern, Dallas, TX 75216, United States
Yang, Y.-C.; Amgen Inc., Thousand Oaks, CA 91320, United States
Wagman, R. B.; Amgen Inc., Thousand Oaks, CA 91320, United States
Siddhanti, S.; Amgen Inc., Thousand Oaks, CA 91320, United States
Grauer, A.; Amgen Inc., Thousand Oaks, CA 91320, United States
Hall, J. W.; Amgen Inc., Thousand Oaks, CA 91320, United States
Jones G, Nguyen T, Sambrook PN, Kelly PJ, Gilbert C, Eisman JA 1994 Symptomatic fracture incidence in elderly men and women: the Dubbo Osteoporosis Epidemiology Study (DOES). Osteoporos Int 4:277-282 (Pubitemid 24291436)
Gielen E, Vanderschueren D, Callewaert F, Boonen S 2011 Osteoporosis in men. Best Pract Res Clin Endocrinol Metab 25:321-335
King AB, Tosteson AN, Wong JB, Solomon DH, Burge RT, Dawson-Hughes B 2009 Interstate variation in the burden of fragility fractures. J Bone Miner Res 24:681-692
Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A 2007 Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 22:465-475 (Pubitemid 46797130)
Johnell O, Kanis JA 2006 An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726-1733 (Pubitemid 44607392)
Haentjens P, Magaziner J, Colón-Emeric CS, Vanderschueren D, Milisen K, Velkeniers B, Boonen S 2010 Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 152:380-390
Kannegaard PN, van der Mark S, Eiken P, Abrahamsen B 2010 Excess mortality in men compared with women following a hip fracture. National analysis of comedications, comorbidity and survival. Age Ageing 39:203-209
Ebeling PR 2008 Clinical practice. Osteoporosis in men. N Engl J Med 358:1474-1482
Kiebzak GM, Beinart GA, Perser K, Ambrose CG, Siff SJ, Heggeness MH2002 Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med 162:2217-2222 (Pubitemid 35231591)
Dawson-Hughes B, Looker AC, Tosteson AN, Johansson H, Kanis JA, Melton 3rd LJ 2012 The potential impact of the National Osteoporosis Foundation guidance on treatment eligibility in the USA: an update in NHANES 2005-2008. Osteoporos Int 23:811-820
Khosla S, Amin S, Orwoll E 2008 Osteoporosis in men. Endocr Rev 29:441-464 (Pubitemid 351831508)
Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A 2000 Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604-610 (Pubitemid 30659471)
Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD 2009 Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res 24:719-725
Orwoll ES, Miller PD, Adachi JD, Brown J, Adler RA, Kendler D, Bucci-Rechtweg C, Readie A, Mesenbrink P, Weinstein RS 2010 Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res 25:2239-2250
Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP 2000 Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 85:3069-3076
Cramer JA, Gold DT, Silverman SL, Lewiecki EM 2007 A system-atic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18:1023-1031 (Pubitemid 47019996)
Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y, San Martin J 2008 Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 93:2149-2157 (Pubitemid 351831529)
Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C 2009 Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756-765
Smith MR, Saad F, Egerdie B, Szwedowski M, Tammela TL, Ke C, Leder BZ, Goessl C 2009 Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol 182:2670-2675
Genant HK, Wu CY, van Kuijk C, Nevitt MC 1993 Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137-1148 (Pubitemid 23261108)
Meier DE, Orwoll ES, Jones JM 1984 Marked disparity between trabecular and cortical bone loss with age in healthy men. Measurement by vertebral computed tomography and radial photon absorptiometry. Ann Intern Med 101:605-612 (Pubitemid 15223296)
Moxness M, Tatarewicz S, Weeraratne D, Murakami N, Wullner D, Mytych D, Jawa V, Koren E, Swanson SJ 2005 Immunogenicity testing by electrochemiluminescent detection for antibodies directed against therapeutic human monoclonal antibodies. Clin Chem 51:1983-1985 (Pubitemid 41368199)
Hochberg Y 1988 A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75:800-802
Wang C, Nieschlag E, Swerdloff RS, Behre H, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FC 2009 ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male 12:5-12
Orwoll ES, Binkley NC, Lewiecki EM, Gruntmanis U, Fries MA, Dasic G 2010 Efficacy and safety of monthly ibandronate in men with low bone density. Bone 46:970-976
Dempster DW 2006 Anatomy and functions of the adult skeleton. In: Favus MJ, ed. Primer on the metabolic bone disease and disorders of mineral metabolism. 6th ed. Washington, DC: American Society for Bone and Mineral Research; 7-11
Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, Hadji P, Hofbauer LC, Alvaro-Gracia JM, Wang H, Austin M, Wagman RB, Newmark R, Libanati C, San Martin J, Bone HG 2009 Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 24:153-161
McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ 2006 Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821-831 (Pubitemid 43290920)
Miller PD, Wagman RB, Peacock M, Lewiecki EM, Bolognese MA, Weinstein RL, Ding B, San Martin J, McClung MR 2011 Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. J Clin Endocrinol Metab 96:394-402
Seeman E, Delmas PD, Hanley DA, Sellmeyer D, CheungAM,Shane E, Kearns A, Thomas T, Boyd SK, Boutroy S, Bogado C, Majumdar S, Fan M, Libanati C, Zanchetta J 2010 Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res 25:1886-1894
Melton 3rd LJ, Khosla S, Atkinson EJ, Oconnor MK, Ofallon WM, Riggs BL 2000 Cross-sectional versus longitudinal evaluation of bone loss in men and women. Osteoporos Int 11:592-599
Fatayerji D, Cooper AM, Eastell R 1999 Total body and regional bone mineral density in men: effect of age. Osteoporos Int 10:59-65 (Pubitemid 29428016)